β-Lactamase inhibitors: a review of the patent literature (2010 – 2013)

Proliferation and significance of clinically relevant β-lactamases

(2013) Karen Bush   Annals of the New York Academy of Sciences

Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011

(2013) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Is the GAIN Act a turning point in new antibiotic discovery?

(2013) Eric D. Brown   CANADIAN JOURNAL OF MICROBIOLOGY

Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds

(2013) Ellie J.C. Goldstein et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Activity of BAL30072 alone or combined with  -lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters

(2013) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of biapenem (RPX2003) combined with the boronate  -lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae

(2013) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance

(2013) Alan P. Johnson et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities

(2012) Bartolomé Moyá et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette ChromosomemecTypes

(2012) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

(2012) Elizabeth B. Hirsch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

(2012) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-β-lactamases

(2012) Pinhong Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions

(2012) L. S. Tzouvelekis et al.   CLINICAL MICROBIOLOGY REVIEWS

Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa

(2012) Daniel J. Wolter et al.   CURRENT PHARMACEUTICAL DESIGN

The Rise of Carbapenem-Resistant Acinetobacter baumannii

(2012) Benjamin A. Evans et al.   CURRENT PHARMACEUTICAL DESIGN

Essentials for Selecting Antimicrobial Therapy for Intra-Abdominal Infections

(2012) Stijn Blot et al.   DRUGS

Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole

(2012) L.J. Dubreuil et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes

(2012) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OXA-48-like carbapenemases: the phantom menace

(2012) L. Poirel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fragment-guided design of subnanomolar  -lactamase inhibitors active in vivo

(2012) O. Eidam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In VitroandIn VivoProperties of BAL30376, a β-Lactam and Dual β-Lactamase Inhibitor Combination with Enhanced Activity against Gram-Negative Bacilli That Express Multiple β-Lactamases

(2011) Malcolm G. P. Page et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes

(2011) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

(2011) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoComparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms

(2011) Catharine C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

(2011) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 2. N-Alkylated and open chain analogs of MK-8712

(2011) Helen Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

(2011) Z. Aktaş et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Metallo-β-lactamases: a last frontier for β-lactams?

(2011) Giuseppe Cornaglia et al.   LANCET INFECTIOUS DISEASES

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

(2011) Jang Hyun Choi et al.   NATURE

A Concise Synthesis of a β-Lactamase Inhibitor

(2011) Ian K. Mangion et al.   ORGANIC LETTERS

Pseudomonas aeruginosa: all roads lead to resistance

(2011) Elena B.M. Breidenstein et al.   TRENDS IN MICROBIOLOGY

In Vitro Potentiation of Carbapenems with ME1071, a Novel Metallo- -Lactamase Inhibitor, against Metallo- -Lactamase- Producing Pseudomonas aeruginosa Clinical Isolates

(2010) Y. Ishii et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Ceftaroline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

(2010) David R. Snydman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against 623 Diverse Strains of Anaerobic Bacteria

(2010) D. M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam  -Lactamase Inhibitor

(2010) T. Stachyra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli

(2010) M. G. P. Page et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients

(2010) L. Zamorano et al.   CLINICAL MICROBIOLOGY AND INFECTION

Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections

(2010) Ioanna Eleftheriadou et al.   DRUGS

Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms

(2010) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of chequerboard combinations of ceftaroline and NXL104 versus  -lactamase-producing Enterobacteriaceae

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus  -lactamase-producing Enterobacteriaceae

(2010) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Design, Synthesis, Crystal Structures, and Antimicrobial Activity of Sulfonamide Boronic Acids as β-Lactamase Inhibitors

(2010) Oliv Eidam et al.   JOURNAL OF MEDICINAL CHEMISTRY

Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa

(2009) J.-M. Rodriguez-Martinez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of NXL104 in Combination with  -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases

(2009) A. Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem

(2009) Timothy A. Blizzard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates

(2009) David M. Livermore et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205

(2008) Ayako Toda et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The spread of CTX-M-type extended-spectrum β-lactamases

(2008) G.M. Rossolini et al.   CLINICAL MICROBIOLOGY AND INFECTION

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum  -lactamases and carbapenemases

(2008) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY